Patheon Closes Acquisition of Agere Pharmaceuticals

Report this content

Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire Agere Pharmaceuticals, Inc., a privately-held CDMO, that specializes in improving the absorption rate of medications (bioavailability). The company will become part of Patheon’s pharmaceutical development services unit and operate as a solubility center of excellence in Bend, Ore.

Patheon Media Relations

Tel: +1 (919) 210-0986

Email:  tyler.gronbach@patheon.com or media@patheon.com

About Patheon

Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.